Related Experiment Videos
Cardiac manifestations of HIV
Majid Sadigh1, Sailaja Puttagunta
1Department of Medicine, St. Mary's Hospital, and Yale Primary Care Residency Program, 56 Franklin Street, Waterbury, CT 06706, USA. msadigh@stmh.org
Insights
Cardiac disease in HIV/AIDS patients is multifactorial, involving direct effects, viruses, and drugs. Antiretroviral therapy-induced lipodystrophy is a key risk factor for ischemic heart disease, with treatment discussed.
Area of Science:
- Cardiology
- Infectious Diseases
- HIV/AIDS Research
Background:
- Cardiac disease in human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is a growing concern.
- Pathogenesis is complex, involving direct toxic effects, viral infections, autoimmunity, nutritional deficits, and medications.
- Clinical presentations encompass pericardial, myocardial, and valvular heart conditions.
Purpose of the Study:
- To review the clinical manifestations of cardiac disease in HIV/AIDS.
- To explore the role of lipodystrophy, a side effect of antiretroviral therapy (ART), in ischemic heart disease.
- To detail the treatment strategies for lipodystrophy in this patient population.
Main Methods:
- Literature review of cardiac manifestations in HIV/AIDS.
- Analysis of the link between lipodystrophy and ischemic heart disease.
- Comprehensive review of lipodystrophy treatment options.
Main Results:
- HIV/AIDS is associated with diverse cardiac pathologies.
- Lipodystrophy, a common complication of ART, is identified as a potential risk factor for ischemic heart disease.
- Effective management of lipodystrophy is crucial for cardiovascular health in HIV/AIDS patients.
Conclusions:
- Cardiac complications are significant in HIV/AIDS management.
- Lipodystrophy management is essential to mitigate ischemic heart disease risk.
- Further research into the multifactorial cardiac impact of HIV/AIDS and its treatment is warranted.
Abstract:
Cardiac disease in the setting of HIV/AIDS has only recently been appreciated. The pathogenesis is multifactorial including direct toxic effects, viruses, autoimmunity, nutritional deficiencies and drugs. The clinical manifestations include pericardial, myocardial and valvular heart disease. Lipodystrophy, caused by anti-retroviral therapy is common and may be a risk factor in ischemic heart disease. The treatment of lipodystrophy is reviewed in detail.